- Home
- MAIA vs VERU Comparison
MAIA vs VERU Comparison
Compare MAIA & VERU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MAIA
- VERU
- Stock Information
- Founded
- MAIA 2018
- VERU 1971
- Country
- MAIA United States
- VERU United States
- Employees
- MAIA N/A
- VERU N/A
- Industry
- MAIA Biotechnology: Pharmaceutical Preparations
- VERU Biotechnology: Pharmaceutical Preparations
- Sector
- MAIA Health Care
- VERU Health Care
- Exchange
- MAIA Nasdaq
- VERU Nasdaq
- Market Cap
- MAIA 56.7M
- VERU 54.6M
- IPO Year
- MAIA 2022
- VERU 1990
- Fundamental
- Price
- MAIA $1.32
- VERU $4.29
- Analyst Decision
- MAIA
- VERU Strong Buy
- Analyst Count
- MAIA 0
- VERU 3
- Target Price
- MAIA N/A
- VERU $33.33
- AVG Volume (30 Days)
- MAIA 594.6K
- VERU 173.0K
- Earning Date
- MAIA 11-11-2025
- VERU 08-12-2025
- Dividend Yield
- MAIA N/A
- VERU N/A
- EPS Growth
- MAIA N/A
- VERU N/A
- EPS
- MAIA N/A
- VERU N/A
- Revenue
- MAIA N/A
- VERU $16,886,419.00
- Revenue This Year
- MAIA N/A
- VERU N/A
- Revenue Next Year
- MAIA N/A
- VERU N/A
- P/E Ratio
- MAIA N/A
- VERU N/A
- Revenue Growth
- MAIA N/A
- VERU 337.24
- 52 Week Low
- MAIA $1.27
- VERU $2.64
- 52 Week High
- MAIA $3.48
- VERU $14.20
- Technical
- Relative Strength Index (RSI)
- MAIA 34.23
- VERU 62.67
- Support Level
- MAIA $1.65
- VERU $4.01
- Resistance Level
- MAIA $1.97
- VERU $4.54
- Average True Range (ATR)
- MAIA 0.12
- VERU 0.30
- MACD
- MAIA -0.05
- VERU -0.03
- Stochastic Oscillator
- MAIA 4.45
- VERU 66.67
About MAIA MAIA Biotechnology Inc.
MAIA Biotechnology Inc is a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer. THIO (6-thio-dG or 6-thio-2 '-deoxyguanosine), its lead asset, is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity. Patients with advanced NSCLC will be treated first with THIO followed a few days later by the immune checkpoint inhibitor Libtayo (cemiplimab), manufactured and commercialized by Regeneron.
About VERU Veru Inc.
Veru Inc is a biopharmaceutical company with a drug development program for the treatment of metabolic diseases, oncology, and acute respiratory distress syndrome (ARDS). The company is also in the late-stage development of certain drugs for the management of breast and prostate cancers. It also has a sexual health program that includes two products, ENTADFI, for the treatment of benign prostatic hyperplasia (BPH) and the FC2 Female Condom (Internal Condom). The company operates in a single segment and generates revenue from the USA which is the key revenue generating market, Brazil, and other regions.